Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation by Naura, A. S. et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
5-1-2008 
Post-allergen challenge inhibition of poly(ADP-ribose) polymerase 
harbors therapeutic potential for treatment of allergic airway 
inflammation 
A. S. Naura 
LSU Health Sciences Center - New Orleans 
C. P. Hans 
LSU Health Sciences Center - New Orleans 
M. Zerfaoui 
LSU Health Sciences Center - New Orleans 
D. You 
LSU Health Sciences Center - New Orleans 
S. A. Cormier 
LSU Health Sciences Center - New Orleans 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Naura, A., Hans, C., Zerfaoui, M., You, D., Cormier, S., Oumouna, M., & Boulares, A. (2008). Post-allergen 
challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic 
airway inflammation. Clinical and Experimental Allergy, 38 (5), 839-846. https://doi.org/10.1111/
j.1365-2222.2008.02943.x 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
Authors 
A. S. Naura, C. P. Hans, M. Zerfaoui, D. You, S. A. Cormier, M. Oumouna, and A. H. Boulares 
This article is available at LSU Digital Commons: https://digitalcommons.lsu.edu/biosci_pubs/899 
Post-allergen challenge inhibition of poly(ADP-ribose)
polymerase harbors therapeutic potential for treatment of allergic
airway inflammation
A. S. Naura, C. P. Hans, M. Zerfaoui, D. You, S. A. Cormier, M. Oumouna1, and A. H. Boulares
Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health
Sciences Center, New Orleans, LA, USA
Summary
Background—Identifying therapeutic drugs that block the release or effects of T-helper type 2
(Th2) cytokines after allergen exposure is an important goal for the treatment of allergic inflammatory
diseases including asthma. We recently showed, using a murine model of allergic airway
inflammation, that poly(ADP-ribose) polymerase (PARP) plays an important role in the pathogenesis
of asthma-related lung inflammation. PARP inhibition, by single injection of a novel inhibitor, thieno
[2,3-c]isoquinolin-5-one (TIQ-A), before ovalbumin (OVA) challenge, prevented airway
eosinophilia in C57BL/6 mice with concomitant suppression of Th2 cytokine production and mucus
secretion.
Objective—To evaluate the efficacy of the drug when it is given after OVA challenge for its possible
therapeutic potential.
Methods—This study was conducted using a murine model of allergic airway inflammation.
Results—A single injection of TIQ-A (6 mg/kg) one or 6 h post-allergen challenge conferred similar
reduction in OVA challenge-induced eosinophilia. More significantly, post-allergen challenge
administration of the drug exerted even better suppression on the production of IL-4, IL-5, IL-13,
and IgE and prevented airway hyperresponsiveness to inhaled-methacholine. The significant
decrease in IL-13 was accompanied by a complete absence of airways mucus production indicating
a potential protection against allergen-induced airway remodelling.
Conclusion—The coincidence of the inflammation trigger and the time of drug administration
appear to be important for the drug’s more pronounced protection. The observed time window for
efficacy, 1 or 6 h after allergen challenge may be of great clinical interest. These findings may provide
a novel therapeutic strategy for the treatment of allergic airway inflammation, including asthma.
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Asthma is, in part, a T-helper type 2 (Th2) lymphocytemediated inflammatory airway disease
characterized by pulmonary eosinophilia, increased mucus production by goblet cells, and
airway hyperresonsiveness (AHR) [1-3]. The presence of high levels of allergen-specific IgE
is a reflection of an aberrant Th2 immune response [4,5]. In recent years, an accumulation of
data from mice and humans has identified Th2 cytokines IL-4, IL-5, and IL-13, as major
contributors to allergy and asthma. Such studies suggest that blocking the release or effects of
these cytokines may have important therapeutic potential. Significant areas of asthma therapy
research and development are emerging, which include humanized monoclonal antibodies
(mAbs) targeting IgE, IL-4, IL-5, TNF, or IL-13 as well as cytokine and chemokine receptors
[6]. Furthermore, removal of cytokines or chemokines has been attempted using soluble
receptors or small molecule receptor antagonists [6-8]. Additionally, drugs have been designed
that block the signal transduction pathways that become activated when cytokines or
chemokines interact with their receptors [6,9]. Overall, these strategies showed very promising
results in experimental animal models of asthma but exhibited serious limitations when applied
to treat the disease in humans both in terms of efficacy and cost [8]. These limitations and
failed clinical trials clearly argue for additional studies to discover new strategies for the
treatment of the disease.
Poly(ADP-ribose) polymerase (PARP)-1 plays an important role in tissue injury associated
with oxidative stress and inflammation. In several pathological situations that involve oxidative
DNA damage, excessive activation of PARP depletes cellular stores of both NAD and its
precursor ATP. This leads to irreversible cytotoxicity and can cause cell death [10,11]. In
addition to its effects through NAD metabolism on cell and tissue homeostasis, PARP is
thought to participate in inflammation by regulating, directly or indirectly, the expression of
several inflammatory factors including adhesion molecules, TNF, ILs, and inducible nitric
oxide synthase [12].
Airway eosinophilia is a consistent characteristic feature of allergic inflammation and asthma
[13]. Eosinophil release lipid mediators, cytokines, and cytotoxic proteins [6,13]. Despite the
fact that the number of eosinophils is associated with asthma severity in human patients, the
actual role of these leucocytes in the pathophysiology of the disease remains elusive. Recently,
Lee et al. [14] and Humbles et al. [15] reported, using transgenic animals deficient in
eosinophils, that eosinophilia is an integral trait of experimental allergic asthma. However,
these two studies reported contradictory findings on the role of eosinophils on AHR.
We recently showed that PARP play a role in eosinophil recruitment into lungs in our
experimental model of allergic airway inflammation [16]. Administration of the novel PARP
inhibitor thieno[2,3-c]isoquinolin-5-one (TIQ-A) before allergen challenge resulted in
suppression of Th2 cytokines, including IL-4, IL-5, and IL-13, and suppression of the ensuing
eosinophil infiltration and associated mucus production in lung airways [16]. Our results led
us to examine the effect of TIQ-A on the eosinophil recruitment when it is administered after
the allergen challenge. This is a clinically more relevant approach for the treatment of
inflammation-associated asthma. Our results show that a single injection of TIQ-A one or 6 h
after allergen challenge significantly suppress the production of Th2 cytokines, the consequent
infiltration of eosinophils and mucus production, and AHR. Taken together, our results show
a strong therapeutic potential of TIQ-A in blocking important traits that result from allergen
exposure.
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Animals, protocols for sensitization and challenge
Mice were bred in a specific-pathogen free facility at LSUHSC, New Orleans, LA, and allowed
unlimited access to sterilized chow and water. Maintenance, experimental protocols, and
procedures were all approved by the LSUHSC Animal Care & Use Committee. C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME, USA).
Six-week-old C57BL/6 mice (n = at least six) were sensitized with intraperitoneally (i.p.)
injections of 100 μg Grade V chicken ovalbumin (OVA) (Sigma-Aldrich, St Louis MO, USA)
mixed with 2 mg aluminum hydroxide in saline once a week for two consecutive weeks. The
mice were then challenged with aerosolized OVA (3% OVA in saline) a week after the second
sensitization in a Plexiglas chamber for 30 min. The OVA aerosol was generated by a Bennett
nebulizer (DeVilbiss, Somerset, PA, USA). Control groups were not sensitized or challenged.
Additional groups of mice received 6 mg/kg TIQ-A (i.p.) 2 h prior, one post, or 6 h post OVA
challenge. The mice used in each experiment were of the same litter or the same family. Mice
were then left to recover and killed 24–48 h later for bronchio-alveolar lavage (BAL) or lung
fixations and processing for histological analysis.
Organ recovery, staining, and T-helper type 2 cytokine and immunoglobulin E assessments
Animals were killed by CO2 asphyxiation and lungs were fixed with formalin for histological
analysis or subjected to BAL. A final volume of 5 mL saline was used for BAL to assess
inflammatory cells (48 h post OVA-challenge) or 1 mL to assess cytokines or IgE (24 h post
OVA-challenge). Formalin fixed lungs were sectioned and subjected to hematoxylin and eosin
(H&E), Periodic Acid-Schiff (PAS) staining using standard protocols. Histological mucin
index was assessed essentially as described [17]. Collected BAL fluids were subjected to cyto-
spin and stained with H&E for the assessment of inflammatory cells. The cytokine assessment
was conducted using the Bio-Rad Bioplex System for mouse Th2 cytokines namely IL-4, IL-5
and IL-13 according to the manufacturer instructions and specifications. OVA-specific IgE
was quantified by a sandwich ELISA (Serotec, Raleigh, NC, USA) essentially as described
[16].
Assessment of pulmonary function
Lung resistance to increasing doses of methacholine (MeCh, Sigma, St Louis, MO, USA; 0,
25, and 50 mg/mL in isotonic saline) was assessed 24 h after OVA challenge using the forced
oscillation technique as previously described [18]. Anesthetized animals were mechanically
ventilated with a tidal volume of 10 mL/kg and a frequency of 2.5 Hz using a computer-
controlled piston ventilator (FlexiVent, SCIREQ; Montreal, Canada). Just before data
collection, the volume history of the respiratory system was standardized by inflating the lungs
to total lung capacity. Resistance data were collected using single compartment model and
plotted after normalization to baseline (i.e. resistance at 0 mg/mL MeCh). Data are plotted as
means ± SEM.
Data analysis
All data are expressed as means ± SD of values from at least six mice per group unless stated
otherwise. PRISM software (GraphPad, San Diego, CA, USA) was used to analyze the
differences between experimental groups by one way ANOVA followed by Dunnett’s multiple
comparison test.
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Comparison of the effects of thieno [2, 3-c] isoquinolin-5-one administration before vs. after
ovalbumin challenge
OVA sensitization and challenge induced a clear and marked perivascular and peribronchial
infiltration by eosinophils in lungs of wild-type mice (Figs 1a and b). Administration of the
PARP inhibitor TIQ-A before OVA-challenge significantly suppressed eosinophil recruitment
(Figs 1a and b), which is consistent with our previous report [16].
We tested the efficacy of TIQ-A in controlling inflammation when administered after allergen
(OVA) challenge. As shown in Fig. 1a, infiltration of inflammatory cells into the airways of
OVA-challenged mice was greatly reduced in animals that received a single TIQ-A i.p.
injection either 1 or 6 h after challenge. An assessment of the number of eosinophils in BAL
fluids showed that post-challenge TIQ-A administration exerted a similar pronounced
reduction in eosinophil recruitment compared with administration of the drug before challenge
(Fig. 1b). These results not only show that PARP plays a critical role in allergen-induced lung
inflammation but also presents PARP inhibition as a potential therapeutic strategy for avoiding
the manifestation of eosinophilia after allergen exposure.
Post-challenge thieno[2,3-c]isoquinolin-5-one administration severely suppress T-helper
type 2 cytokine and immunoglobulin E production after ovalbumin challenge
The expression of Th2-type cytokines and production of IgE are critical factors in promoting
allergen-induced lung inflammation. Cytokine expression is crucial for the generation and
recruitment of eosinophils into the lung upon allergen exposure [19,20]. Accordingly, we
compared the effects of PARP inhibition post vs. prior OVA challenge on the expression of
the Th2 cytokines IL-4, IL-5, IL-13. Cytokine production was measured from BAL fluids 24
h after challenge. As expected, OVA exposure induced a robust production of each of these
cytokines (Figs 2a—c). TIQ-A administration post-challenge suppressed production of Th2
cytokines even more than TIQ-A administration before OVA challenge (Figs 2a—c). These
results not only demonstrate that PARP inhibition exerts its anti-inflammatory effect by
reducing the production of Th2 cytokines but also show that post-challenge TIQ-A
administration is more efficacious in blocking such an allergen-induced airway inflammatory
response.
We next examined whether the marked reduction in eosinophil recruitment into airways of
OVA-challenged mice conferred by PARP inhibition was associated with a reduction in IgE
production. Levels of OVA-specific IgE were measured in BAL fluid samples 24 h post-
challenge. Figure 2d shows that TIQ-A caused a moderate reduction in the levels of OVA-
specific IgE when administered before OVA challenge but almost completely blocked IgE
production when administered after OVA challenge. These results are consistent with the effect
of TIQ-A administration on IL-4.
Post-challenge thieno[2,3-c]isoquinolin-5-one administration completely stopped mucus
production in airways of ovalbumin-challenged mice
Mucus hypersecretion is a consistent trait of allergic inflammatory response, especially in fatal
episodes of asthma [21]. A number of reports have provided evidence that support a critical
role for IL-13 in mucus hypersecretion during asthma [17]. Strategies that block IL-13
production, such as administration of the soluble IL-13Ra2-Ig, or through IL-13 gene deletion
in mice, prevent airway production of mucus [6]. Given the severe effect of PARP inhibition
post allergen-challenge on IL-13 production, we wanted to determine its effect on mucus
hypersecretion in our experimental murine model. Lung sections from different experimental
mouse groups were stained with PAS to detect mucus-secreting goblet cells.
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While lungs of OVA-challenged wild-type mice exhibited substantial hyper-production of
mucus, as evidenced by the pronounced red staining of goblet cells, the lungs of OVA-
challenged wild-type mice that received TIQ-A either 1–6 h after challenge exhibited a
complete absence of PAS-positive goblet cells (Fig. 3a). Quantitative assessment of mucus
production expressed as a histological mucin index show that while treatment with TIQ-A
before OVA challenge significantly reduced mucus production, post-challenge treatment with
the drug completely blocked such mucus production (Fig. 3b).
Post-challenge thieno[2,3-c]isoquinolin-5-one administration prevents methacholine-
induced airway hyperrresponsiveness in ovalbumin-challenged mice
We next assessed whether the protective effects of PARP inhibition by TIQ-A against
eosinophilia and induction of the Th2 response coincided with prevention of AHR, a major
hallmark of human asthma. Lung resistance to increasing doses of MeCh was assessed using
the forced oscillation technique (see ‘Materials and methods’). Figure 4 shows that
administration of TIQ-A post-OVA challenge almost completely blocked AHR to inhaled
MeCh at a dose of 50 mg/mL 24 h after OVA exposure.
Taken together, our results strongly suggest a great clinical potential for PARP inhibition in
blocking the inflammatory phenotype and AHR associated with allergen exposure such as that
observed in asthma.
Discussion
Asthma is a complex disease that involves a variety of cell and non-cell components [1,2,22].
Antigen exposure initiates this disease in sensitive subjects and results in an array of events
leading to the generation of CD4+ Th2 cells, IgE production, recruitment of eosinophils into
the AHR, hyperplasia of goblet cells and the ensuing mucus production [20,23]. CD4+ Th2
cells play a pivotal role in orchestrating the allergic response, including effects on the
production of key Th2 cytokines necessary for the build up of eosinophils in the lungs as well
as activation of B lymphocytes to generate IgE [20].
It is now widely accepted that airway inflammation is the key factor underlying the
pathogenesis of asthma [1,22]. While corticosteroids remain the most important anti-
inflammatory treatment for asthma, they are rather nonspecific in their actions [6,7]. Their use
also raises concerns over side-effects and compliance issues, particularly in children and
adolescents [7]. Thus, there is much effort underway to develop novel specific and safer
therapies for the treatment of asthma. Inhibitors of cytokines figure prominently in these novel
therapeutic approaches [6,9].
As Th2 lymphocytes play a key role in orchestrating the eosinophilic inflammatory response
in asthma, blocking the release or effects of these cytokines may have therapeutic potential.
Numerous studies suggest that blocking individual Th2 cytokines have shown some promise,
but not complete success, in the treatment of asthma [6,8]. Inhibition of IL-5 with mAb has
been effective in reducing circulating and airway eosinophils, but, disappointingly, does not
appear to be beneficial to functional responses [8,24]. IL-4 blocking antibodies inhibit allergen-
induced AHR, goblet cell metaplasia and pulmonary eosinophilia in a murine model [6].
Inhibition of IL-4, despite promising early results in asthma, has been disappointing at the
clinical level [25]. A blocking antibody to IL-13 is very effective in reversing chronic allergic
inflammation, indicating the potential for IL-13 blockage in the treatment of chronic asthma
[7]. However, Perkins et al. [26] have recently shown that IL-4 can induce all of the acute
changes in airway inflammation that have been associated with IL-13, including BAL fluid
eosinophilia, AHR, and goblet cell hyperplasia, in the absence of IL-13 signaling.
Naura et al. Page 5













Taken together, these finding suggest that attempts to block specific cytokines may not be
adequate for blocking chronic inflammation in asthma, as so many cytokines are involved and
there is considerable redundancy of effects. Development of drugs that have a more general
effect on cytokine synthesis may be more successful. Accordingly, PARP inhibition by TIQ-
A following allergen exposure plays a critical role in the amelioration of the pathogenic process
of allergic-induced lung inflammation in mice. TIQ-A down-regulates the production of Th2
cytokines IL-4, IL-5, and IL-13 and IgE in a concerted manner as well as AHR as measured
in response to inhaled MeCh. Tissue eosinophilia [27] and expression of eotaxin-1 [28], a
critical chemokine for eosinophil recruitment to the airways after allergen exposure, are
important variables in animal models of asthma. However, the effect of PARP inhibition on
such variables remains to be determined.
We have reported that PARP inhibition before allergen exposure protects against infiltration
of eosinophils and mucus production into lung airways by suppressing Th2 cytokine production
[16]. However, our current findings show an equally potent action of TIQ-A, a novel PARP
inhibitor, against the allergen-induced airway eosinophilia and mucus production, when it is
given after the allergen exposure. The effects of TIQ-A administration on mucus production
is consistent with its effect on IL-13 and the other cytokines. Further, we show for the first
time that PARP inhibition almost completely prevents AHR. Because most asthma symptoms
are associated with accidental exposure to known or unknown allergens, it becomes crucially
relevant to determine whether promising new drugs with preventive outcomes, would also
harbor a therapeutic potential.
Our findings suggest that timing of drug administration is crucial for its maximal beneficial
action. The reduction in eosinophilia was accompanied by more pronounced suppression of
IL-4, IL-5, IL-13, and IgE and an absence of mucus production by airway goblet cells. These
effects were also accompanied with the prevention of AHR, a major feature of human asthma.
Importantly, the marked protection observed as late as 6 h after allergen exposure enhances
the clinical potential of the drug considerably. These findings broaden the current perspectives
in our understanding of the functions of PARP in an allergen-induced airway and present new
insight into the immunopharmacological effects of PARP inhibition in blocking critical
inflammatory traits associated with asthma.
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Effect of PARP inhibition by TIQ-A on eosinophil recruitment following OVA sensitization
and challenge. Mice received an i.p. injection of TIQ-A (6 mg/kg) or vehicle alone 2 h prior,
1 h post, or 6 h post-OVA challenge; mice were killed 48 h later. Lungs were either fixed with
formalin or subjected to BAL. (a) Lung sections were stained with H&E and analyzed by light
microscopy; bars: 4 μm. (b) BAL fluids were collected and centrifuged; cells were then
differentially stained, and eosinophils were counted. Data are expressed as percent eosinophils
from total cell number collected by BAL. Data are means ± SD of values from at least six mice
per group. *Difference from challenged mice without TIQ-A treatment, P<0.01; #difference
from TIQ-A-treated mice before OVA-challenge, P<0.01. PARP, poly(ADP-ribose)
polymerase; TIQ-A, thieno[2,3-c]isoquinolin-5-one; BAL, bronchio-alveolar lavage; H&E,
hematoxylin and eosin; OVA, ovalbumin; i.p., intraperitoneally.
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Effect of PARP inhibition by TIQ-A on Th2 cytokine production following OVA sensitization
and challenge. Mice were sensitized to and challenged with OVA or left unchallenged.
Different experimental groups received prior or post-challenge administration of TIQ-A as
described in Fig. 1. Mice were killed 24 h later, after which they were subjected to BAL. BAL
fluids were collected and centrifuged. The supernatant was used for cytokine assessment using
the Bio-Rad Bioplex system (a—c) or IgE (d) levels by ELISA. Data are given as means ± SD
of values obtained from at least six mice per group. *Difference from challenged mice without
TIQ-A treatment, P<0.01; #difference from TIQ-A-treated mice before OVA-challenged,
P<0.01; ?difference is not statistically significant. PARP, poly(ADP-ribose) polymerase; TIQ-
A, thieno[2,3-c]isoquinolin-5-one; BAL, bronchio-alveolar lavage; Th2, T-helper type 2;
OVA, ovalbumin.
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Effect of PARP inhibition by TIQ-A on mucus hypersecretion by goblet cells in airways of
OVA-sensitized and challenged mice. C57BL/6 mice were sensitized to OVA and subjected
to a challenge with aerosolized OVA or left unsensitized and unchallenged. Mice received an
i.p. injection of TIQ-A or vehicle alone 2 h prior, 1 h post, or 6 h post-OVA challenge. Mice
were killed 48 h later. Lungs were fixed with formalin. Lung sections were stained with PAS,
after which histological analysis was conducted by light microscopy; bars: 4 μm; arrows
indicate PAS positive goblet cells. (b) The extent of mucus production (histological mucin
index) was assessed using Image-Pro Plus software. Data are means ± SD of values from at
least six mice per group. Difference from challenged mice without TIQ-A treatment,
P<0.01; #difference from TIQ-A-treated mice before OVA-challenged, P<0.01. PARP, poly
(ADP-ribose) polymerase; TIQ-A, thieno[2,3-c]isoquinolin-5-one; BAL, bronchio-alveolar
lavage; H&E, hematoxylin and eosin; OVA, ovalbumin; i.p., intraperitoneally.
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Effect of PARP inhibition by TIQ-A on airway hyperreactivity in OVA-sensitized and
challenged mice. C57BL/6 mice were sensitized to OVA and subjected to a challenge with
aerosolized OVA (∎). A group of mice received an i.p. injection of TIQ-A (▴) or vehicle alone
(●)after OVA exposure. Lung resistance to increasing doses of MeCh was assessed using the
forced oscillation technique. Lung resistance is plotted as a function of increasing doses of
inhaled MeCh, using single compartment model and expressed as mean ± SEM. n = 5 per
group. *Difference from challenged mice without TIQ-A treatment, P < 0.01. PARP, poly
(ADP-ribose) polymerase; TIQ-A, thieno[2,3-c]isoquinolin-5-one; BAL, bronchio-alveolar
lavage; MeCh, methacholine; OVA, ovalbumin; i.p. intraperitoneally.
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